Foghorn Therapeutics Files Routine 8-K on Jan 16 Event
Ticker: FHTX · Form: 8-K · Filed: Jan 17, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Jan 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance
TL;DR
**Foghorn Therapeutics filed a routine 8-K, no immediate impact on stock.**
AI Summary
Foghorn Therapeutics Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024. This filing is a standard current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a routine disclosure without specific details about executive changes or compensatory arrangements in the provided text. For investors, this filing itself doesn't reveal new material information about the company's operations or financial health, but rather serves as a procedural update that could precede more detailed disclosures.
Why It Matters
This filing is a standard procedural update, indicating that Foghorn Therapeutics is complying with SEC regulations. Without further details, it doesn't immediately impact investment decisions but signals potential upcoming disclosures.
Risk Assessment
Risk Level: low — This 8-K is a standard procedural filing and does not contain information that indicates a significant risk to the company or its investors.
Analyst Insight
A smart investor would note this routine filing and await further, more detailed disclosures from Foghorn Therapeutics Inc. to understand any material impact, as this filing itself provides no specific actionable information.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — the registrant filing the 8-K
- January 16, 2024 (date) — date of the earliest event reported
- January 17, 2024 (date) — date the 8-K was filed
- 001-39634 (other) — Commission File Number
FAQ
What is the purpose of this 8-K filing by Foghorn Therapeutics Inc.?
This 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a disclosure of an event that occurred on January 16, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 16, 2024.
What is the filing date of this 8-K for Foghorn Therapeutics Inc.?
The 8-K was filed on January 17, 2024.
Where is Foghorn Therapeutics Inc.'s principal executive office located?
Foghorn Therapeutics Inc.'s principal executive office is located at 500 Technology Square, Ste 700, Cambridge, MA 02139.
What is Foghorn Therapeutics Inc.'s Commission File Number?
Foghorn Therapeutics Inc.'s Commission File Number is 001-39634.
Filing Stats: 603 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-17 16:09:00
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
Filing Documents
- fhtx-20240116.htm (8-K) — 31KB
- 0001628280-24-001504.txt ( ) — 157KB
- fhtx-20240116.xsd (EX-101.SCH) — 2KB
- fhtx-20240116_lab.xml (EX-101.LAB) — 24KB
- fhtx-20240116_pre.xml (EX-101.PRE) — 13KB
- fhtx-20240116_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael J. LaCascia Michael J. LaCascia Chief Legal Officer Date: January 17, 2024